Blinatumomab Added to Chemotherapy in Infant Lymphoblastic Leukemia

Clinical Implications of Minimal Residual Disease Detection in Infants With KMT2A-Rearranged Acute Lymphoblastic Leukemia Treated on the Interfant-06 Protocol

(2021) Janine Stutterheim et al.   JOURNAL OF CLINICAL ONCOLOGY

Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia

(2021) Patrick A. Brown et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia

(2021) Franco Locatelli et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children’s Oncology Group trial AALL0631

(2021) Patrick A. Brown et al.   LEUKEMIA

Outcomes for Australian children with relapsed/refractory acute lymphoblastic leukaemia treated with blinatumomab

(2021) Rosemary Sutton et al.   PEDIATRIC BLOOD & CANCER

KMT2A Rearrangements Are Associated with Lineage Switch Following CD19 Targeting CAR T-Cell Therapy

(2021) Adam J. Lamble et al.   BLOOD

Blinatumomab for Infant Acute Lymphoblastic Leukaemia

(2020) Katherine Clesham et al.   BLOOD

Involvement of the central nervous system in acute lymphoblastic leukemia: opinions on molecular mechanisms and clinical implications based on recent data

(2020) Lennart Lenk et al.   CANCER AND METASTASIS REVIEWS

A risk-stratified therapy for infants with acute lymphoblastic leukemia: a report from the JPLSG MLL-10 trial

(2020) Daisuke Tomizawa et al.   BLOOD

Chimeric antigen receptor T‐cell therapy for marrow and extramedullary relapse of infant acute lymphoblastic leukemia

(2020) Amy Moskop et al.   PEDIATRIC BLOOD & CANCER

Outcome of Infants Younger Than 1 Year With Acute Lymphoblastic Leukemia Treated With the Interfant-06 Protocol: Results From an International Phase III Randomized Study

(2019) Rob Pieters et al.   JOURNAL OF CLINICAL ONCOLOGY

Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia

(2018) Nicola Gökbuget et al.   BLOOD

Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy

(2016) R. Gardner et al.   BLOOD

Successful Therapy Reduction and Intensification for Childhood Acute Lymphoblastic Leukemia Based on Minimal Residual Disease Monitoring: Study ALL10 From the Dutch Childhood Oncology Group

(2016) Rob Pieters et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia

(2016) Arend von Stackelberg et al.   JOURNAL OF CLINICAL ONCOLOGY

Lineage Switch in MLL-Rearranged Infant Leukemia Following CD19-Directed Therapy

(2016) Ahmad Rayes et al.   PEDIATRIC BLOOD & CANCER

Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment

(2015) G. Zugmaier et al.   BLOOD

Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration

(2015) Ching-Hon Pui et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study

(2015) Max S Topp et al.   LANCET ONCOLOGY

Outcome of relapsed infant acute lymphoblastic leukemia treated on the interfant-99 protocol

(2015) E M C Driessen et al.   LEUKEMIA

Intensified chemotherapy without SCT in infant ALL: Results from COG P9407 (Cohort 3)

(2014) ZoAnn E. Dreyer et al.   PEDIATRIC BLOOD & CANCER

Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival

(2011) Max S. Topp et al.   JOURNAL OF CLINICAL ONCOLOGY